Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Monica Klaybor

Internal Medicine New Orleans, LA Medical Doctor

NPI 1083238844 CMS profile 8377409

1401 Foucher St, New Orleans, LA 70115

Open in the dashboard

General payments

$3,479

40 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Monica Klaybor of New Orleans, LA is reported in the CMS Open Payments database as having received $3,479 across 40 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,538 19
2024 General $1,430 14
2023 General $511 7

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Monica Klaybor
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Monica Klaybor were reported at $1,538. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Monica Klaybor Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $0 $119 $33–$402 $114
2021 $0 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $511 $149 $45–$519 $160
2024 $1,430 $154 $47–$537 $164
2025 $1,538 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Abbott Laboratories $644 7 payments
  2. Shockwave Medical, Inc $411 2 payments
  3. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $336 5 payments
  4. Amgen Inc. $328 4 payments
  5. Recor Medical Inc $295 2 payments
  6. Abiomed $265 3 payments
  7. Laborie Medical Technologies Corp. $180 2 payments
  8. BridgeBio Pharma, Inc. $147 1 payment
  9. Pfizer Inc. $134 2 payments
  10. Kiniksa Pharmaceuticals International, plc $130 1 payment
  11. Other $610 11 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $3,074 38 payments
  2. Education $405 2 payments
Products named General payments · program years 2023–2025
  1. LifeVest $336 5 payments
  2. Paradise Ultrasound Renal Denervation System $295 2 payments
  3. ENSITE $270 1 payment
  4. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $267 1 payment
  5. Repatha $190 3 payments
  6. Impella $165 2 payments
  7. XARELTO $149 3 payments
  8. Attruby $147 1 payment
  9. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $144 1 payment
  10. THORATEC HEARTMATE 3 LVAS IMPLANT KIT $135 1 payment
  11. Other $934 15 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

376

Median for Internal Medicine: 777

Drug cost

$128,864

Median for Internal Medicine: $73,373

Branded share of claims

38.6%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 42 $42,768
Entresto Sacubitril/Valsartan Brand 18 $27,830
Eliquis Apixaban Brand 22 $22,071
Xarelto Rivaroxaban Brand 18 $20,702
Repatha Sureclick Evolocumab Brand 25 $13,513
Metoprolol Succinate Generic 27 $385
Carvedilol Generic 47 $336
Atorvastatin Calcium Generic 41 $317
Ezetimibe Generic 11 $314
Losartan Potassium Generic 26 $271

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$3,292

Medicare's payments for the services billed

Medicare patients

37

Average age 72

Services billed

43

21 women, 16 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 75%
Atrial fibrillation 62%
Arthritis 62%
Chronic kidney disease 51%
Depression 41%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Scientific Affairs, LLC $114
  • Janssen Pharmaceuticals, Inc $35
$149 18 —
Arcalyst
  • Kiniksa Pharmaceuticals International, plc $130
$130 — —
Repatha
  • Amgen Inc. $127
$127 25 —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $31
$31 42 —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

40 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record